Viewpoint on handling anti-TNF failure in psoriasis

Archives of Dermatological Research

Volumn 305, Issue 10, 2013, Pages 945-950

  Bracke, Stefanie ^a   Lambert, Jo ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anti drug antibodies (ADA); Anti TNF; Biologics; Drug trough levels; Immunogenicity; Psoriasis

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ALGORITHM; ARTICLE; CLINICAL DECISION MAKING; DERMATITIS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHRODERMA; HUMAN; NAUSEA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RADIOIMMUNOASSAY; RASH; REMISSION; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-12; INTERLEUKIN-23; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892172926     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-013-1418-6     Document Type: Article

References (26)

1. (EMEA) EAftEoMP (2007) Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006
2. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105(5):1133-1139
3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2010) Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 69(5):817-821
4. Chavez-Lopez MA, Delgado-Villafana J, Gallaga A, Huerta-Yanez G (2005) Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol (Madr) 33(5):291-292
5. Daien CI, Daien V, Parussini E, Dupuy AM, Combe B, Morel J (2012) Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 39(8):1533-1538
6. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P (2007) The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 25(1):40-46
7. Edrees AF, Misra SN, Abdou NI (2005) Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNFalpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 23(4):469-474
8. Guenther LC (2011) Combination therapy of biologics with traditional agents in psoriasis. Skin Therapy Lett 16(6):1-3
9. Herrier RN (2011) Advances in the treatment of moderate-tosevere plaque psoriasis. Am J Health Syst Pharm 68(9):795-806
10. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics R (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56(1):13-20
11. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ (2011) The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70(2):284-288
12. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ (2012) Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 71(1):88-91
13. Lecluse LL, de Groot M, Bos JD, Spuls PI (2009) Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 161(4):948-951
14. Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ (2010) Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 146(2):127-132
15. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA (2008) Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 159(3):527-536
16. Leman J, Burden AD (2012) Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol 167(Suppl 3):12-20
17. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, investigators Ps (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665-1674
18. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study G (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21):2014-2022
19. Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4(10):1248-1254
20. Mazzotta A, Esposito M, Costanzo A, Chimenti S (2009) Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 10(5):319-324
21. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68(5):702-709
22. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303(1):1-10
23. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366(9494):1367-1374
24. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ (2009) Ormerod AD (2009) British Association of Dermatologists' guidelines for biologic interventions for psoriasis. Br J Dermatol 161(5):987-1019
25. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T (2010) How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 130(4):933-943
26. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T (2011) Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70(7): 1208-1215